Latest Breaking News On - A phase 1 trial nct04429087 - Page 1 : comparemela.com

Treatment with at least 90 μg/kg of the novel DLLC-targeting T-cell–engager BI 764532 was well tolerated and led to tumor shrinkage in patients with small cell lung cancer and neuroendocrine carcinoma.

Martin wermkeTechnische universitLung cancerWorld conference on lung cancerBi 76453Small cell lung cancerNeuroendocrine carcinomaA phase 1 trial nct04429087